Therapeutics News and Research

RSS

New algorithm can help scientists predict gene and drug interactions

Researchers from Mount Sinai School of Medicine have developed a new computational method that will make it easier for scientists to identify and prioritize genes, drug targets, and strategies for repositioning drugs that are already on the market. By mining large datasets more simply and efficiently, researchers will be able to better understand gene-gene, protein-protein, and drug/side-effect interactions. The new algorithm will also help scientists identify fellow researchers with whom they can collaborate.

25 Jul 2012

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.

24 Jul 2012

Durata closes initial public offering of 8,625,000 shares of common stock

Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.

24 Jul 2012

Queen's University, Cirdan Imaging partner to develop novel techniques for cancer detection

The development of novel medical imaging techniques to revolutionise cancer detection and treatment will be the result of a new partnership announced today between Queen's University Belfast and Cirdan Imaging Ltd.

24 Jul 2012

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

BrainStorm Cell Therapeutics announced today that it has completed the planned interim safety review of its Phase I/II ALS (Amyotrophic Lateral Sclerosis) clinical trial, indicating that autologous transplantation of the Company's cell therapy was well-tolerated, appears to be safe for use, and did not present any undue risks to the study participants.

23 Jul 2012

PTC Therapeutics completes $30M financing

PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors.

23 Jul 2012

Researchers uncover protein structure that regulates blood cell formation and activity

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.

23 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

Scientists identify inhibitors of key enzyme involved in survival of malaria parasite

An international team of scientists, led by researchers from the Department of Pediatrics at the University of California, San Diego School of Medicine, have identified the first reported inhibitors of a key enzyme involved in survival of the parasite responsible for malaria. Their findings, which may provide the basis for anti-malarial drug development, are currently published in the online version of the Journal of Medicinal Chemistry.

20 Jul 2012

BrainStorm completes registered public offering of common stock

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common stock at a price per share of $0.29 and warrants to purchase 14,864,229 shares of common stock at an exercise price of $0.29 per share, representing gross proceeds of $5,747,502.

20 Jul 2012

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Interferon beta not associated with less progression of disability in patients with RRMS

Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.

18 Jul 2012

Venom protein could treat Duchenne muscular dystrophy

While Spider-Man is capturing the imagination of theatergoers, real-life spider men in Upstate New York are working intently to save a young boy's life. It all began in 2009, when Jeff Harvey, a stockbroker from the Buffalo suburbs, discovered that his grandson, JB, had Duchenne muscular dystrophy. The disease is fatal. It strikes only boys, causing their muscles to waste away.

17 Jul 2012

UIC develops new tool to guide decisions about safe and effective medication use

A new tool to guide decisions about safe and effective medication use has been developed at the University of Illinois at Chicago College of Pharmacy.

17 Jul 2012

New Alzheimer's model derived from skin cells of patients may prove to be more accurate

Researchers at the Alzheimer's Association International Conference 2012 (AAIC 2012) today reported the creation of a new model of Alzheimer's derived from the skin cells of people with the disease that were reprogramed into Alzheimer's brain cells.

17 Jul 2012

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.

17 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

WTG to launch ‘Early Drug Development Summit’ in Berlin

With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.

16 Jul 2012

Therapeutics News and Research

New algorithm can help scientists predict gene and drug interactions

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Durata closes initial public offering of 8,625,000 shares of common stock

Queen's University, Cirdan Imaging partner to develop novel techniques for cancer detection

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

PTC Therapeutics completes $30M financing

Researchers uncover protein structure that regulates blood cell formation and activity

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Study explores role of L. reuteri against foodborne infection

Scientists identify inhibitors of key enzyme involved in survival of malaria parasite

BrainStorm completes registered public offering of common stock

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Interferon beta not associated with less progression of disability in patients with RRMS

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

Venom protein could treat Duchenne muscular dystrophy

UIC develops new tool to guide decisions about safe and effective medication use

New Alzheimer's model derived from skin cells of patients may prove to be more accurate

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

WTG to launch ‘Early Drug Development Summit’ in Berlin

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News